CCCC (C4 Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CCCC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-13 | LEONARD REYNO | Chief Medical Officer | MIXED | — | — |
| 2026-07-02 | DONNA ROY GROGAN | Director | A | — | — |
| 2026-07-02 | Kenneth Carl Anderson | Director | A | — | — |
| 2026-06-26 | Ronald Harold Wilfred Cooper | Director | A | — | — |
| 2026-06-26 | DONNA ROY GROGAN | Director | A | — | — |
| 2026-06-26 | Utpal Koppikar | Director | A | — | — |
| 2026-06-26 | Laura Bessen | Director | A | — | — |
| 2026-06-26 | Owen Hughes | Director | A | — | — |
| 2026-06-26 | Stephen Fawell | Director | A | — | — |
| 2026-06-26 | Kenneth Carl Anderson | Director | A | — | — |
| 2026-06-26 | Steven L. Hoerter | Director | A | — | — |
| 2026-06-04 | Kenneth Carl Anderson | Director | M | — | — |
| 2026-04-03 | DONNA ROY GROGAN | Director | A | — | — |
| 2026-04-03 | Kenneth Carl Anderson | Director | A | — | — |
| 2026-02-18 | LEONARD REYNO | Chief Medical Officer | MIXED | — | — |
| 2026-02-18 | Mark Mossler | Chief Accounting Officer | MIXED | — | — |
| 2026-02-18 | Kelly Schick | Chief People Officer | MIXED | — | — |
| 2026-02-18 | Andrew Hirsch | President & CEO | MIXED | — | — |
| 2026-02-18 | Kendra Adams | Chief Financial Officer | MIXED | — | — |
| 2026-02-18 | Scott N Boyle | Chief Business Officer | MIXED | — | — |
| 2026-02-18 | Paige Mahaney | Chief Scientific Officer | MIXED | — | — |
| 2026-01-16 | LEONARD REYNO | Chief Medical Officer | Sell | — | — |
| 2026-01-05 | DONNA ROY GROGAN | Director | A | — | — |
| 2026-01-05 | Kenneth Carl Anderson | Director | A | — | — |
| 2025-10-30 | Paige Mahaney | Chief Scientific Officer | MIXED | — | — |
| 2025-10-03 | DONNA ROY GROGAN | Director | A | — | — |
| 2025-10-03 | Kenneth Carl Anderson | Director | A | — | — |
| 2025-09-19 | Kendra Adams | Chief Financial Officer | MIXED | — | — |
| 2025-07-15 | LEONARD REYNO | Chief Medical Officer | MIXED | — | — |
| 2025-07-14 | LEONARD REYNO | Chief Medical Officer | F | — | — |
| 2025-07-02 | DONNA ROY GROGAN | Director | A | — | — |
| 2025-07-02 | Kenneth Carl Anderson | Director | A | — | — |
| 2025-06-20 | DONNA ROY GROGAN | Director | A | — | — |
| 2025-06-20 | Utpal Koppikar | Director | A | — | — |
| 2025-06-20 | Ronald Harold Wilfred Cooper | Director | A | — | — |
| 2025-06-20 | Laura Bessen | Director | A | — | — |
| 2025-06-20 | Kenneth Carl Anderson | Director | A | — | — |
| 2025-06-20 | Steven L. Hoerter | Director | A | — | — |
| 2025-06-20 | Owen Hughes | Director | A | — | — |
| 2025-06-20 | Stephen Fawell | Director | A | — | — |
| 2025-04-03 | DONNA ROY GROGAN | Director | A | — | — |
| 2025-04-03 | Kenneth Carl Anderson | Director | A | — | — |
| 2025-02-18 | Mark Mossler | Chief Accounting Officer | F | — | — |
| 2025-02-18 | Andrew Hirsch | President & CEO | MIXED | — | — |
| 2025-02-18 | LEONARD REYNO | Chief Medical Officer | MIXED | — | — |
| 2025-02-18 | Jolie Siegel | Chief Legal Officer | MIXED | — | — |
| 2025-02-18 | Kendra Adams | Chief Financial Officer | MIXED | — | — |
| 2025-02-18 | Kelly Schick | Chief People Officer | MIXED | — | — |
| 2025-02-18 | Paige Mahaney | Chief Scientific Officer | A | — | — |
| 2025-02-18 | Scott N Boyle | Chief Business Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 1,975,381 | — |
| — | Director | 1,805,252 | — |
| — | President & CEO | 1,123,145 | — |
| — | Director | 792,682 | — |
| — | Director | 489,542 | — |
| — | Chief Financial Officer | 402,342 | — |
| — | Chief Medical Officer | 379,803 | — |
| — | Chief Scientific Officer | 336,910 | — |
| — | Chief People Officer | 308,885 | — |
| — | Chief Business Officer | 306,070 | — |
| — | Director | 146,531 | — |
| — | Chief Scientific Officer | 131,371 | — |
| — | Chief Accounting Officer | 75,184 | — |
| — | Director | 74,853 | — |
| — | Chief Legal Officer | 54,353 | — |
| — | Chief Financial Officer | 32,686 | — |
| — | Director | 31,681 | — |
| — | Chief Medical Officer | 20,097 | — |
| — | Director | 11,380 | — |
| — | Director | 5,667 | — |
| — | Chief Financial Officer | 5,263 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CCCC quote page; the site-wide leaderboard is on the insider transactions hub.